

Draft of the Portuguese Programme on Rare Diseases

José Marques Robalo

Deputy Director-General of Health Ministry of Health Portugal





DRAFT OF THE PORTUGUESE PROGRAMME WORKING GROUP

- The programme was developed by a workgroup of experts from these fields:
 - health care,
 - medical research,
 - clinical laboratories,
 - orphan drug agency,
 - administration.





NATIONAL HEALTH PLAN 2004 - 2010





DRAFT OF THE PORTUGUESE PROGRAMME

 This programme was on public consultation until January 31st, 2008

 Workshops were held with the stakeholders (health care professionals, researchers, drug industry and patient associations).





DRAFT OF THE PORTUGUESE PROGRAMME

 The final draft incorporates all the inputs from the public consultation and from the stakeholders.





MAIN GOALS

- Improve the national response to nonsatisfied health needs of people with rare diseases and their families;
- Improve health care quality for people with rare diseases.





SPECIFIC GOALS

- Establish the national network of reference centres for rare diseases;
- Improve access to adequate care for people with rare diseases;
- Improve the mechanism of integrated management of rare diseases;
- Improve knowledge and research on rare diseases;
- Promote therapeutic innovation on medicines for rare diseases;
- Ensure the trans-national cooperation in the EU and CPLP (Community of Portuguese Language Countries).





All individuals affected by rare diseases, considered within their families and communities.





ACTION PLAN

Implementation: 2008 – 2010

Consolidation: 2010-2015





STRATEGIES

Three main directions:

- Intervention
- Training
- Collect data and information analysis





INTERVENTION STRATEGIES

- Propose specific financial rules for accredited reference centres;
- Define criteria for early diagnosis of rare diseases;
- Guarantee long term, health and social care to people with rare diseases;
- Propose specific support and inclusion to children with rare diseases;
- Create and disseminate guidelines of "best practices" for the promotion of clinical quality and patient safety of people with rare diseases;
- Monitor efficiency and safety of the orphan drugs.





TRAINING STRATEGIES

- Promote specific training on rare diseases for health professionals;
- Create and disseminate self-assistance manuals;
- Disseminate scientific information and the available resources.





STRATEGIES DATA COLLECTION AND INFORMATION ANALYSIS

- Develop partnerships between health services, investigation centres and patient associations;
- Monitor health gains resulting from the programme implementation.





ACCOMPANIMENT AND EVALUATION

The Directorate-General of Health, supported by a national expert committee should develop and monitor a set of indicators, such as:

- Total number of accredited reference centres;
- Total number of rare diseases with integrated management;
- Total number of technical guidelines on "best practices" developed.





TIMELINE AND BUDGET

The timeline for each strategy has been outlined in great detail.

 A strict budget is under development, considering the planned timeline of each strategy.





CONCLUSIONS



José Robalo

Directorate-General for Health

Portugal

www.dgs.pt

jrobalo@dgs.pt

